Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Hamad, Nada  [Clear All Filters]
2024
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, et al. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica. 2024.
2023
Murthy GSubramania, Kim S, Estrada-Merly N, Abid MBilal, Aljurf M, Assal A, Badar T, Badawy SM, Ballen K, Beitinjaneh A, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023.
Saccardi R, Putter H, Eikema D-J, Busto MPaula, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk FAyuketang, Baldomero H, et al. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2023.
Moore J, Hamad N, Gottlieb DJ, Bajel A, Ritchie DS, Yeung DT, Greenwood M, Purtill D, Tran S, Solterbeck A, et al. Early cessation of calcineurin inhibitors is feasible post haploidentical blood stem cell transplant-the ANZHIT-1 study. Blood Adv. 2023.
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, et al. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023.
Coutsouvelis J, Kirkpatrick CM, Dooley M, Spencer A, Kennedy G, Chau M, Huang G, Doocey R, Copeland T-S, Do L, et al. Incidence of sinusoidal obstruction syndrome/veno-occlusive disease and treatment with defibrotide in allogeneic transplant: A multicentre Australasian registry study. Transplant Cell Ther. 2023.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Blennerhassett R, Othman J, Biscoe A, Kliman D, Mills G, Blyth E, Micklethwaite K, Kwan J, Bilmon I, Bhattacharyya A, et al. Long term outcomes of corticosteroid graft versus host disease prophylaxis in peripheral blood allogeneic hematopoietic stem cell transplant: A comparative cohort analysis. Intern Med J. 2023.
2022
Tokaz MC, Baldomero H, Cowan AJ, Saber W, Greinix H, Koh MBc, Kröger N, Mohty M, Galeano S, Okamoto S, et al. An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia. Transplant Cell Ther. 2022.
Perram J, Schoemans H, Hamad N. First, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation. Lancet Haematol. 2022;9(7):e476-e477.
2020
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7(7):e511-e522.
Othman J, Greenwood M, Moore J, Larsen S, Watson A-M, Arthur C, Bhattacharyya A, Bilmon I, Blyth E, Bryant A, et al. Unrelated donor transplant recipients given Thymoglobuline have superior GRFS when compared to matched related donor recipients transplanted without ATG. Biol Blood Marrow Transplant. 2020.
2019
Gerstl B, Sullivan E, Koch J, Wand H, Ives A, Mitchell R, Hamad N, Anazodo A. Reproductive outcomes following a stem cell transplant for a haematological malignancy in female cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2019.
2015
Hamad N, Shanavas M, Michelis FV, Uhm J, Gupta V, Seftel M, Kuruvilla J, Lipton JH, Messner HA, Kim DDong Hwan. Mycophenolate based GVHD prophylaxis is not inferior to methotrexate in myeloablative related donor stem cell transplantation. Am J Hematol. 2015.